Project Grant HT94252410886
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
This $661,501 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of California, Los Angeles (UCLA) for the period of September 1, 2024 through August 31, 2027. The award will fund research to develop AAV (adeno-associated virus) vectors targeted to muscle and muscle stem cells, which offer improved therapeutic efficacy and safety for treating Duchenne muscular dystrophy. UCLA, through...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $551,250.00 to the University of California, Los Angeles (UCLA) to develop 3D-Bridge antisense oligonucleotides and a stem cell-targeting modality for skipping exons of Duchenne muscular dystrophy. The award period is from July 1, 2024 to June 30, 2026. Through this grant, UCLA will leverage its research and administrative capabilities to advance novel therapeutic...
The University of California, Los Angeles (UCLA) was awarded a $418,357 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support UCLA's efforts to enhance delivery of adeno-associated virus (AAV)-CRISPR to muscle stem cells from September 30, 2022 to September 29, 2024. As the sub-awardee, UCLA will leverage the funding to conduct research that aims to transform military and...
This federal Project Grant award of $345,664.00 from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, supports an advanced biomedical research initiative led by Royal Holloway University of London. The research project aims to develop an AAV-based microdystrophin gene therapy for Duchenne muscular dystrophy, with a focus on enhancing immune protection through capsid bioengineering. The award period spans from December 1, 2024 to November 30,...
The University of California, Los Angeles (UCLA) was awarded a $1,920,201.00 Project Grant from the Defense Health Agency (DHA) on August 1, 2023 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports UCLA's research to conduct single nuclei transcriptome analysis of Duchenne muscular dystrophy (DMD) to identify disease-modifying targets. The research will be conducted at UCLA's facilities in Los Angeles, California over the 3-year period...
This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $7,348,261.00 to the University of California, Los Angeles (UCLA) to conduct a clinical evaluation of 4-aminopyridine in hereditary spinocerebellar ataxia. The award, which runs from August 1, 2025 to July 31, 2027, supports advanced biomedical research aimed at transforming healthcare for military service members and the general public. The funding...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,708,955 project grant to the University of Washington to support a 3-year research study on "Enhanced Gene Therapy for DMD Using Larger Dystrophins and Lower Vector Doses". The grant, which commenced on September 15, 2023 and will be completed by September 14, 2026, aims to advance gene therapy approaches for the treatment of Duchenne muscular dystrophy (DMD). The University...
This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $572,306 in funding to the University of Washington for a 3-year research project to develop "ENHANCED GENE THERAPY FOR DMD USING LARGER DYSTROPHINS AND LOWER VECTOR DOSES". The aim is to advance gene therapy approaches for treating Duchenne muscular dystrophy (DMD) by utilizing larger dystrophin gene constructs and reducing the required vector doses. The...